Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.
Discussing Lung Cancer NGS Testing and EGFR Treatment Strategies
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their approaches.
Read More
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Listen
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior treatment.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Wildfires’ Impact on Patients With Cancer: Lessons in Crisis Response
The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and learning for future disaster preparedness.
AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation
The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung cancer.